Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26724064 | 1.00 | EPHX1 (0.34) | EPHX1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL11953213 | 0.84 | ATM (0.44) | ATMPIK3CD | |
| SCHEMBL14610923 | 0.84 | ATM (0.44) | ATMPIK3CD | |
| SCHEMBL16186342 | 0.84 | ATM (0.40) | EPHX1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL10033281 | 0.84 | ATM (0.44) | ATMPIK3CD | |
| SCHEMBL12869332 | 0.84 | ATM (0.40) | EPHX1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL15077296 | 0.84 | ATM (0.40) | EPHX1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL19650723 | 0.84 | ATM (0.40) | EPHX1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL21621509 | 0.84 | ATM (0.40) | EPHX1CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL15077292 | 0.84 | ATM (0.40) | EPHX1CHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | EPHX1 3226/4885CHRNB2 158/4885CHRNA3 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.